Clinical Study

Intravenous Lidocaine: Old-School Drug, New Purpose—Reduction of Intractable Pain in Patients with Chemotherapy Induced Peripheral Neuropathy

Table 1

Clinical characteristics.

Patient numberSex/age (yr)Type of malignancyType of chemotherapy NCI-CTC gradePain duration (mo)HADSPain locationAnalgesic treatment before study

1M/62Colorectal cancerOxaliplatin, capecitabine41019Upper & lower extremityAmitriptyline, pregabalin carbamazepine

2M/45Testis CarcinomaCisplatinum4226Lower extremityAmitriptyline, pregabalin nortriptyline, topiramate methadone, etoricoxib oxynorm

3F/70Colorectal cancerOxaliplatin46018Upper & lower extremityAmitriptyline, pregabalin duloxetine, diazepam acetaminophen

4F/54Breast CancerDocetaxel,
capecitabine,
cyclophosphamide,
trastuzumab
41617Lower extremityAmitriptyline, pregabalin carbamazepine, fentanyl oxynorm, diclofenac hydromorphone, acetaminophen

5F/53Chronic myeloid leukemiaCyclophosphamide,
imatinib
4609Upper & lower extremityAmitriptyline, pregabalin tramadol, gabapentin ibuprofen, mirtazapine acetaminophen

6M/53Chronic lymphoid leukemiaCisplatinum,
cyclophosphamide,
fludarabine,
cytarabine,
etoposide
430Upper & lower extremityAmitriptyline, pregabalin fentanyl, acetaminophen

7F/32Ovarian CancerCisplatinum,
paclitaxel,
carboplatin
11617Lower extremityPregabalin

8M/64Non-Hodgkin LymphomaCyclophosphamide,
etoposide,
cytarabine
4180Upper & lower extremityDuloxetine, fentanyl oxynorm

9F/41Colorectal cancerOxaliplatin,
capecitabine,
bevacizumab
227Upper & lower extremityOxycontin, oxynorm

M: male; F: female; NCI-CTC: National Cancer Institute-Common Toxicity Criteria; HADS: Hospital Anxiety and Depression scale. HADS questionnaire is missing in 3 patients.